Bausch Health yesterday announced a nationwide recall of all Emerade brand epinephrine auto-injectors (0.3mg and 0.5mg strengths) sold in Canada due to the probability of device failure.
Testing by the company identified the potential risk of the device failing to activate or activating prematurely when dropped. Affected lots were sold between April 2022 and May 2023.
Consumers are urged to return their Emerade auto-injectors to their pharmacy for a suitable replacement as soon as possible and are urged not to return or dispose of their Emerades until a replacement is obtained. Consumers are advised to consult their pharmacists to ensure they understand how to properly use the replacement auto-injector.
If a life-threatening allergic reaction (anaphylaxis) happens before you can get a replacement, use your recalled Emerade and then seek emergency medical attention.
See the announcement on the Government of Canada health site here.